Cargando…

Addressing Patients’ Priorities as a Strategy to Improve Value

The individual patient perspective is critical to inform assessments of value that drive treatment decisions. There are many elements that patients and providers must weigh, and novel decision support tools are needed to help patients clarify their preferences and goals for treatment and, ultimately...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Yu-Ning, Roach, Nancy, Meropol, Neal J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2016
Materias:	Value in Cancer Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189625/ https://www.ncbi.nlm.nih.gov/pubmed/27742905 http://dx.doi.org/10.1634/theoncologist.2016-0184

Ejemplares similares

A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients?
por: Wollins, Dana S., et al.
Publicado: (2016)

Value-Based Care in Lung Cancer
por: Eaton, Keith D., et al.
Publicado: (2016)

Value: The Next Frontier in Cancer Care
por: Goulart, Bernardo H.L.
Publicado: (2016)

New Frameworks to Assess Value of Cancer Care: Strengths and Limitations
por: Schnipper, Lowell E., et al.
Publicado: (2016)

Those Who Pay Have a Say: A View on Oncology Drug Pricing and Reimbursement
por: Newcomer, Lee N.
Publicado: (2016)

Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World
por: Goldstein, Daniel A., et al.
Publicado: (2016)

Getting Past No in Cancer Care
por: Kolodziej, Michael
Publicado: (2016)

Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions
por: Peppercorn, Jeffrey
Publicado: (2017)

End‐of‐Life Care Matters: Palliative Cancer Care Results in Better Care and Lower Costs
por: Dalal, Shalini, et al.
Publicado: (2017)

Development of a Questionnaire to Assess Patient Priorities in Hip Fracture Care
por: Turner, Naomi, et al.
Publicado: (2020)

265 The design of a virtual museum to address social disconnection and pain among individuals with chronic pain (IWCP)
por: Koebner, Ian, et al.
Publicado: (2022)

Commentary: Developing best-practice guidelines for the reporting of E-values
por: VanderWeele, Tyler J, et al.
Publicado: (2020)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss
por: Mashayekhi, Mona, et al.
Publicado: (2022)

364 Identification of Symptom-Based Phenotypes in PASC Patients through Bipartite Network Analysis: Implications for Patient Triage and Precision Treatment Strategies
por: Bhavnani, Suresh K., et al.
Publicado: (2022)

382 Strategies for commercializing non-patentable innovations developed at CTSA hubs
por: Quanbeck, Andrew, et al.
Publicado: (2022)

Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies
por: Garrison, Louis P, et al.
Publicado: (2021)

The effectiveness and value of novel acute treatments for migraine: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Atlas, Steven J, et al.
Publicado: (2023)

The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Pandey, Rajshree, et al.
Publicado: (2021)

The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2023)

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

The effectiveness and value of aducanumab for Alzheimer’s disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Synnott, Patricia G, et al.
Publicado: (2021)

Big data, observational research and P-value: a recipe for false-positive findings? A study of simulated and real prospective cohorts
por: Veronesi, Giovanni, et al.
Publicado: (2020)

298 Feasibility of A Dietary Sodium Reduction Intervention Using mHealth Technology to Improve Adherence in Hypertensive Patients
por: Ko, Jisook, et al.
Publicado: (2022)

The effectiveness and value of novel treatments for cystic fibrosis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2021)

Improving gender equity in critical care medicine: a protocol to establish priorities and strategies for implementation
por: Parsons Leigh, Jeanna, et al.
Publicado: (2020)

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2022)

Oral treatments for outpatient COVID-19: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2023)

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A., et al.
Publicado: (2020)

318 Building A Better CAR: Improving CAR-T Trafficking in Cancer Therapy
por: Hong, Yeonsun, et al.
Publicado: (2022)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2022)

The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2022)

The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p137brs6l3fsb71mdis4l0spce